Patents Assigned to Pfizer
  • Patent number: 7825254
    Abstract: The invention pertains to heteroaromatic compounds that serve as effective phosphodiesterase (PDE) inhibitors. In particular, the invention relates to said compounds which are selective inhibitors of PDE10. The invention also relates to intermediates for preparation of said compounds; pharmaceutical compositions comprising said compounds; and the use of said compounds in a method for treating certain central nervous system (CNS) or other disorders.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: November 2, 2010
    Assignee: Pfizer Inc.
    Inventors: Patrick R. Verhoest, Christopher J. Helal, Dennis J. Hoover, John M. Humphrey
  • Patent number: 7824679
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: November 2, 2010
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Publication number: 20100273794
    Abstract: This invention provides a compound of the formula (I): or a pharmaceutically acceptable salt thereof, and compositions containing such compounds and the use of such compounds for the manufacture of medicament for gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.
    Type: Application
    Filed: July 7, 2010
    Publication date: October 28, 2010
    Applicant: Pfizer Inc.
    Inventors: Yasuhiro Katsu, Satoru Iguchi, Hiroki Sone, Chikara Uchida, Takashi Kojima
  • Patent number: 7820648
    Abstract: The present invention relates to a compound of the formula 1 or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, salt thereof, wherein R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. The invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: December 20, 2006
    Date of Patent: October 26, 2010
    Assignees: Pfizer Inc, Pfizer Products Inc
    Inventors: Samit Kumar Bhattacharya, Michael Joseph Luzzio, Donn Gregory Wishka, Gonghua Pan, Arthur Douglas Brosius, Joel Thomas Arcari, James Alfred Southers, Jr., Kendra Louise Nelson, Jun Xiao
  • Publication number: 20100266629
    Abstract: The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI3), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj-prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo-bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.
    Type: Application
    Filed: June 22, 2010
    Publication date: October 21, 2010
    Applicant: PFIZER INC
    Inventors: Paul J. Dominowski, Michael John Huether, Mark D. Goodyear
  • Patent number: 7815907
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: October 19, 2010
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Bruce D Cohen, Jean Beebe, Penelope E Miller, James D Moyer, Jose R Corvalan, Michael Gallo
  • Patent number: 7812040
    Abstract: This invention is directed to a compound of the formula Ia or Ib, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastro-i
    Type: Grant
    Filed: June 12, 2006
    Date of Patent: October 12, 2010
    Assignee: Pfizer Inc.
    Inventor: Travis T Wager
  • Publication number: 20100255538
    Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies.
    Type: Application
    Filed: April 8, 2010
    Publication date: October 7, 2010
    Applicants: AMGEN FREMONT INC., PFIZER INC.
    Inventors: Bruce D. Cohen, Jean Beebe, Penelope E. Miller, James D. Moyer, Jose R. Corvalan, Michael Gallo
  • Patent number: 7807797
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: October 5, 2010
    Assignees: Amgen Fremont Inc., Pfizer Inc.
    Inventors: Douglas Charles Hanson, Mark Joseph Neveu, Eileen Elliott Mueller, Jeffrey Herbert Hanke, Steven Christopher Gilman, C. Geoffrey Davis, Jose Ramon Corvalan
  • Patent number: 7807838
    Abstract: The present invention relates to methods and compounds useful in the preparation of compounds of the formula (I).
    Type: Grant
    Filed: August 16, 2006
    Date of Patent: October 5, 2010
    Assignee: Pfizer Inc.
    Inventors: Christopher Frederick Matthews, Robert William Scott, John Lloyd Tucker
  • Patent number: 7803805
    Abstract: This invention relates to novel amorphous and crystallline forms of 3-{(3R,4R)-4-methyl-3-[methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-piperidin-1-yl}-3 -oxo-propionitrile mono citrate salt, useful as inhibitors of protein kinases, and to their methods of preparation.
    Type: Grant
    Filed: January 10, 2005
    Date of Patent: September 28, 2010
    Assignee: Pfizer Inc.
    Inventors: Mark E. Flanagan, Zheng J. Li
  • Patent number: 7803832
    Abstract: The invention relates to a sulfonamide compound of formula (I) or a pharmaceutically, veterinarily or agriculturally acceptable salt or solvate thereof, where the groups R1-R5 are described in the description, to compositions comprising such compounds, processes for their synthesis and their use as parasiticides.
    Type: Grant
    Filed: December 1, 2009
    Date of Patent: September 28, 2010
    Assignees: Pfizer Inc., Pfizer Products Inc.
    Inventors: Douglas James Critcher, Nigel Derek Arthur Walshe, Christelle Lauret
  • Publication number: 20100234314
    Abstract: The present invention relates to a method of treating a lymphoma in a dog comprising administering to a dog in need of such treatment a therapeutically effective amount of idarubicin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 15, 2008
    Publication date: September 16, 2010
    Applicant: PFIZER INC.
    Inventors: Pamela Jo Berlinski, Steven Glenn Kamerling
  • Patent number: 7795244
    Abstract: Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.
    Type: Grant
    Filed: June 30, 2008
    Date of Patent: September 14, 2010
    Assignee: Pfizer Inc.
    Inventors: Katherine Elizabeth Brighty, Anthony Marfat, Dale M. McLeod, John P. O'Donnell
  • Patent number: 7795243
    Abstract: Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.
    Type: Grant
    Filed: June 28, 2007
    Date of Patent: September 14, 2010
    Assignee: Pfizer, Inc.
    Inventors: Katherine E. Brighty, Anthony Marfat, Dale G. McLeod, John P. O'Donnell
  • Patent number: 7795447
    Abstract: The present invention relates to compounds of the Formula I wherein R1, R2, R3, R4, R6, R7 and A are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: September 14, 2010
    Assignee: Pfizer Inc
    Inventors: Michael A. Brodney, Karen J. Coffman
  • Patent number: 7795252
    Abstract: The present invention provides for methods of treating neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders using compounds of the following structure: The compounds are therefore useful as neuroprotective and neuroregenerative, anti-proliferative, and anti-inflammatory agents.
    Type: Grant
    Filed: June 9, 2009
    Date of Patent: September 14, 2010
    Assignee: Pfizer Inc.
    Inventors: Edmund Idris Graziani, Kevin Pong, Jerauld S. Skotnicki
  • Publication number: 20100227829
    Abstract: The invention provides polymorphs of a motilide having a structure represented by formula Ia
    Type: Application
    Filed: April 16, 2010
    Publication date: September 9, 2010
    Applicant: PFIZER INC.
    Inventors: Peter J. Licari, Jorge L. Galazzo, Greg O. Buchanan, Alexander Redvers Eberlin, Mark D. Eddleston
  • Patent number: 7790169
    Abstract: The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV).
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: September 7, 2010
    Assignee: Pfizer Inc.
    Inventors: David E. Lowery, Sing Rong, Paul M. Guimond, Paula M. Clare, Cassius M. Tucker, Thomas Jack Newby
  • Patent number: RE41783
    Abstract: A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: September 28, 2010
    Assignee: Pfizer Inc.
    Inventors: Todd A. Blumenkopf, Mark E. Flanagan, Michael J. Munchhof